WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or N-oxide and pharmaceutically acceptable salts thereof, wherein

R^1 is selected from the group consisting of

(a) Hydrogen,

(b) halo,

(c) $-C_{0-6}$alkyl-aryl,

(d) $-C_{0-6}$alkyl-heteroaryl,

(e) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(f) $-C_{0-6}$alkyl–C_{3-6}cycloalkyl, and

(g) –heteroC_{0-6}alkyl;

R^2 is selected from the group consisting of

(a) Hydrogen,

(b) halo,

(c) $-C_{0-6}$alkyl-aryl,

(d) $-C_{0-6}$alkyl-heteroaryl,

(e) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(f) $-C_{0-6}$alkyl–C_{3-6}cycloalkyl, and

(g) –heteroC_{0-6}alkyl;

or R^1 and R^2 are joined so that together with the atoms to which they are attached there is formed a saturated or unsaturated ring with 0-4 heteroatoms, selected from phenyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$, $-CF_3$, aryl, heteroaryl, and heteroC_{1-6}alkyl;

R^3 is selected from the group consisting of

(a) Hydrogen,

(b) halo,

(c) $-C_{0-6}$alkyl-aryl,

(d) $-C_{0-6}$alkyl-heteroaryl,

(e) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(f) $-C_{0-6}$alkyl–C_{3-6}cycloalkyl, and

(g) –heteroC_{0-6}alkyl;

R^4 is selected from the group consisting of

(a) Hydrogen,

(b) halo,

(c) $-C_{0-6}$alkyl-aryl,

(d) $-C_{0-6}$alkyl-heteroaryl,

(e) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(f) $-C_{0-6}$alkyl–C_{3-6}cycloalkyl, and

(g) –heteroC_{0-6}alkyl;

or R^3 and R^4 are joined so that together with the atoms to which they are attached there is formed a saturated or unsaturated ring with 0-4 heteroatoms, selected from phenyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$, $-CF_3$, aryl, heteroaryl, and heteroC_{1-6}alkyl;

R^5 is selected from the group consisting of

(a) Hydrogen,

(b) $-C_{0-6}$alkyl-aryl,

(c) $-C_{0-6}$alkyl-heteroaryl,

(d) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(e) $-C_{0-6}$alkyl–C_{3-6}cycloalkyl, and

(f) –heteroC_{0-6}alkyl;

wherein R^5 choices (b), (c), (d), (e) and (f) are each optionally substituted with a substituent selected from hydroxyl, halo, $-NO_2$ and CF_3;

R^6 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-3}$alkyl,

wherein R^6 choices (b) is optionally substituted with a substituent selected from hydroxyl, halo, $-NO_2$ and CF_3;

or R^5 and R^6 are joined so that together with the atoms to which they are attached there is formed a saturated or unsaturated ring with 0-4 heteroatoms, selected from phenyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$, $-CF_3$, aryl, heteroaryl, and heteroC_{1-6}alkyl;

R^7 is selected from the group consisting of

(a) Hydrogen,
(b) $-C_{0-3}$alkyl-aryl,
(c) $-C_{0-3}$alkyl-heteroaryl,
(d) $-C_{1-6}$alkyl,
(e) $-C_{0-3}$alkyl$-C_{3-6}$cycloalkyl, and
(f) –heteroC_{0-6}alkyl;

wherein R^7 choices (b), (c), (d), (e) and (f) are each optionally substituted with a substituent selected from hydroxyl, halo, $-NO_2$ and CF_3;

R^8 is selected from the group consisting of

(a) Hydrogen,
(b) $-C_{0-3}$alkyl-aryl,
(c) $-C_{0-3}$alkyl-heteroaryl,
(d) $-C_{1-6}$alkyl,
(e) $-C_{0-3}$alkyl$-C_{3-6}$cycloalkyl, and
(f) –heteroC_{0-6}alkyl;

wherein R^8 choices (b), (c), (d), (e) and (f) are each optionally substituted with a substituent selected from hydroxyl, halo, $-NO_2$ and CF_3;

or R^6 and R^8 are joined so that together with the atoms to which they are attached there is formed a saturated or unsaturated ring with 1-4 heteroatoms, selected from phenyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$, $-CF_3$, aryl, heteroaryl, and heteroC_{1-6}alkyl;

or R^7 and R^8 are joined so that together with the atoms to which they are attached there is formed a saturated or unsaturated ring with 0-4 heteroatoms, selected from phenyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$, $-CF_3$, aryl, heteroaryl, and heteroC_{1-6}alkyl;

R9 is selected from the group consisting of

(a) C1-6alkyl,

(b) C3-6cycloalkyl,

(c) aryl, and

(d) heteroaryl; and

X is selected from the group consisting of

(a) C_{1-6}alkylene,

(b) O,

(c) S,

(d)$S(O)_2$,

(e) NR^9, and

(f) C(O),

with the proviso that either R^1 and R^2 or R^3 and R^4 must be joined together to form a ring.

2. A compound according to claim 1

R^1 is selected from the group consisting of

(a) hydrogen,

(b) phenyl or naphthyl,

(c) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(d) $-O-C_{1-6}$alkyl; and

R^2 is selected from the group consisting of

(a) hydrogen,

(b) phenyl or naphthyl,

(c) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms

(d) $-O-C_{1-6}$alkyl;

or R^1 and R^2 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl, naphthyl and cyclohexyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$ and $-CF_3$.

3. A compound according to claim 2

R^1 and R^2 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl, naphthyl and cyclohexyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$ and $-CF_3$.

4. A compound according to claim 1 wherein:

R^3 is selected from the group consisting of

(a) hydrogen,

(b) phenyl or naphthyl,

(c) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms

(d) $-O-C_{1-6}$alkyl; and

R^4 is selected from the group consisting of

(a) hydrogen,

(b) phenyl, naphthyl or pyridyl,

(c) $-C_{1-6}$alkyl, optionally substituted with 1, 2 or 3 halo atoms,

(d) $-O-C_{1-6}$alkyl;

or R^3 and R^4 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl and cyclohexyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$ and $-CF_3$.

5. A compound according to claim 4 wherein:

R^3 and R^4 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl and cyclohexyl, said ring optionally mono or di-substituted with sustituents independently selected from hydroxyl, halo, $-C_{1-6}$alkyl, $-O-C_{1-6}$alkyl, $-NO_2$ and $-CF_3$.

6. A compound according to claim 1 wherein:

R^5 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-3}$alkyl,

(c) phenyl or naphthyl,

(d) $-C_{3-6}$cycloalkyl.

7. A compound according to claim 1 wherein:

R^6 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-3}$alkyl;

R^7 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-6}$alkyl,

(c) –C_{1-4}alkylphenyl; and

R^8 is selected from the group consisting of

(a) hydrogen,

(b) –C_{1-6}alkyl;

or R^6 and R^8 are joined so that together with the atoms to which they are attached there is formed a piperidine or pyridine or ring, optionally mono- or di-substituted with substituents selected from the group consisting of hydroxyl, –O–C_{1-6}alkl and –C_{1-6}alkyl;

or R^7 and R^8 are joined so that together with the atoms to which they are attached there is formed a piperidine, morpholine, pyridine, pyrazole, imidazole or tetrazole ring, optionally mono- or di-substituted with substituents selected from the group consisting of hydroxyl, –OC_{1-6}alkl and –C_{1-6}alkyl.

8. A compound according to claim 1 wherein:

X is $CH_2CH_2CH_2$.

9. A compound according to claim1 of Formula II



II

wherein:

R^5 is selected from the group consisting of

(a) hydrogen,

(b) –C_{1-3}alkyl,

(c) phenyl or naphthyl,

(d) –C_{3-6}cycloalkyl;

R^6 is

(a) hydrogen,

(b) –C_{1-3}alkyl;

R^7 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-4}$alkyl,

(c) $-C_{1-2}$alkylphenyl;

R^8 is $-C_{1-4}$alkyl;

R^{10} and R^{11} are each selected from the group consisting of Hydrogen, hydroxyl, halo, $-C_{1-3}$alkyl, $-O-C_{1-3}$alkyl, $-NO_2$ and $-CF_3$; and

X is $CH_2CH_2CH_2$.

10. A compound according to claim 9 wherein:

R6 is hydrogen.

11. A compound according to claim 10 wherein

R^5 is selected from the group consisting of $-C_{1-3}$alkyl, phenyl, naphthyl and $-C_{3-6}$cycloalkyl.

12. A compound according to claim 1 selected from the group consisting of:





or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition for treating an indication mediated by the binding of an $\alpha_2\delta$ subunit of voltage gated calcium channel, comprising a therapeutically effective amount a of a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable acrrier.

14. A composition according to claim 16, said composition further comprising i) an opiate agonist, ii) an opiate antagonist, iii) an mGluR5 antagonist, iv) a 5HT receptor agonist, v) a 5HT receptor antagonist, vi) a sodium channel antagonist, vii) an NMDA receptor agonist, viii) an NMDA receptor antagonist, ix) a COX-2 selective inhibitor, x) an NK1 antagonist, xi) a non-steroidal anti-inflammatory drug, xii) a GABA-A receptor modulator, xiii) a dopamine agonist, xiv) a dopamine antagonist, xv) a selective serotonin reuptake inhibitor, xvi) a tricyclic antidepressant drug, xvii) a norepinephrine modulator, xviii) L-DOPA, xix) buspirone, xx) a lithium salt, xxi) valproate, xxii) neurontin, xxiii) olanzapine, xxiv) a nicotinic agonist, xxv) a nicotinic antagonist, xxvi) a muscarinic agonist, xxvii) a muscarinic antagonist, xxviii) a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), xxix) a heroin substituting drug, xxx) disulfiram, or xxxi) acamprosate.

15. A composition according to claim 1, wherein said heroin substituting drug is methadone, levo-alpha-acetylmethadol, buprenorphine or naltrexone.

16. A method of treatment of neuropathic pain comprising a step of administering an effective amount of a compound according to claim 1.

17. A method of treatment or prevention of pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

18. A method of treatment or prevention of a pain disorder wherein said pain disorder is acute pain, persistent pain, chronic pain, inflammatory pain, or neuropathic pain, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

19. A method of treatment or prevention of anxiety, depression, bipolar disorder, psychosis, drug withdrawal, tobacco withdrawal, memory loss, cognitive impairment, dementia, Alzheimer's disease, schizophrenia or panic comprising the step of administering a therapeutically

effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

20. A method of treatment or prevention of disorders of extrapyramidal motor function comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

21. The method of claim 20 wherein said disorder of extrapyramidal motor function is Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome, or tardive dyskinesia.

22. A method of treatment or prevention of anxiety disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

23. A method of claim 22 wherein said anxiety disorder is panic attack, agoraphobia or specific phobias, obsessive-compulsive disorders, post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder, eating disorder, substance-induced anxiety disorder, or nonspecified anxiety disorder.

24. A method of treatment or prevention of neuropathic pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

25. A method of treatment or prevention of Parkinson's Disease comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

26. A method of treatment or prevention of depression comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

27. A method of treatment or prevention of epilepsy comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

28. A method of treatment or prevention of inflammatory pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

29. A method of treatment or prevention of cognitive dysfunction comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

30. A method of treatment or prevention of drug addiction, drug abuse and drug withdrawal comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

31. A method of treatment or prevention of bipolar disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

32. A method of treatment or prevention of circadian rhythm and sleep disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

33. The method of Claim 32 wherein the circadian rhythm and sleep disorders are shift-work induced sleep disorder or jet-lag.